Results 91 to 100 of about 12,608 (240)

Nicotine dependence and neuropsychotic effects of varenicline

Безопасность и риск фармакотерапии, 2018
Varenicline is a partial agonist of nicotinic acetylcholine receptors for the therapy of nicotine addiction. The efficacy and safety of the use of varenicline in the treatment of nicotine dependence have been demonstrated in clinical trial EAGLES.
T. M. Bukatina, A. S. Kazakov, R. N. Alyautdin, T. V. Romanova, I. I. Snegireva   +4 more
doaj   +1 more source

Chronic and Idiopathic Pancreatitis—A Personalized Treatment Approach

United European Gastroenterology Journal, Volume 13, Issue 1, Page 116-124, February 2025.
ABSTRACT Chronic pancreatitis is a fibroinflammatory disease of the pancreas with heterogeneous clinical features and a significant socioeconomic burden. Assessing its aetiology and early diagnosis of associated complications remain challenging. Personalized therapy necessitates precise knowledge of the genetic, biological, and clinical differences ...
Julian Cardinal von Widdern, Jonas Rosendahl, Christoph Ammer‐Herrmenau   +2 more
wiley   +1 more source

Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial

Tobacco Induced Diseases, 2016
Introduction Varenicline is an effective smoking cessation medication. Some concern has been raised that its use may precipitate adverse cardiovascular events although no patho-physiological mechanism potentially underlying such an effect has been ...
Helge Haarmann, Alexandra Gossler, Peter Herrmann, Slavtcho Bonev, Xuan Phuc Nguyen, Gerd Hasenfuß, Stefan Andreas, Tobias Raupach   +7 more
doaj   +1 more source

Understanding the mechanisms of change in social norms around tobacco use: A systematic review and meta‐analysis of interventions

Addiction, Volume 120, Issue 2, Page 215-235, February 2025.
Abstract Background and Aims Tobacco use spreads through social networks influencing social norms around tobacco use. However, the social norms scholarship is extremely diverse and occasionally conflicting, complicating efforts to understand how best to leverage social norms to reduce tobacco use.
Shaon Lahiri, Jeffrey B. Bingenheimer, W. Douglas Evans, Yan Wang, Ben Cislaghi, Priyanka Dubey, Bobbi Snowden   +6 more
wiley   +1 more source

Varenicline: Implications for the Field

Journal of Smoking Cessation, 2007
AbstractVarenicline tartrate (Champix) is the first in a new class of therapy for smoking cessation and has been available on NHS prescription since December 2006. It has received approval from The National Institute for Health and Clinical Excellence (NICE) and the Scottish Medicines Consortium and NICE final guidance was issued in July 2007 ...
openaire   +2 more sources

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence

Alzheimer's &Dementia, Volume 21, Issue 4, April 2025.
Vincent Planche, Suzanne Schindler, David S. Knopman, Giovanni Frisoni, Douglas Galasko, Joshua D. Grill, Lon Schneider, Jason Karlawish, Nicolas Villain   +8 more
wiley   +1 more source

Drug-induced liver injury due to varenicline: a case report

BMC Gastroenterology, 2012
Background Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the ...
Sprague David, Bambha Kiran
doaj   +1 more source

Guideline for pharmacological treatment of schizophrenia 2022

Neuropsychopharmacology Reports, Volume 45, Issue 1, March 2025.
Japanese Society of Neuropsychopharmacology, Japanese Society of Clinical Neuropsychopharmacology   +1 more
wiley   +1 more source

Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation

eLife, 2017
To better understand smoking cessation, we examined the actions of varenicline (Chantix) during long-term nicotine exposure. Varenicline reduced nicotine upregulation of α4β2-type nicotinic receptors (α4β2Rs) in live cells and neurons, but not for ...
Anitha P Govind, Yolanda F Vallejo, Jacob R Stolz, Jing-Zhi Yan, Geoffrey T Swanson, William N Green   +5 more
doaj   +1 more source

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial—Correction [PDF]

, 2006

openalex   +1 more source